Peripersonal Space Representation in Upper Limb Segmental Exclusion
NCT ID: NCT07349173
Last Updated: 2026-01-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
60 participants
OBSERVATIONAL
2026-01-15
2028-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Stability of Hemiparetic Patients During a Daily Complex Task
NCT07082036
fNIRS Study of Effort-dependent Brain Activations During Pointing Movements of the Upper Limb in Post-stroke Patients and Healthy Subjects
NCT06116006
Enhancing Abilities in Amputees and Patients With Peripheral Neuropathy Through Restoration of Sensory Feedback
NCT04217005
A Music-based VR Intervention for Upper Limb Motor Rehabilitation in Hemiparetic Patients
NCT04977609
Strategy Training for Optimizing Awareness in Rehabilitation for Individuals With Spatial Neglect Living
NCT07331896
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study is monocentric, observational, with a matched control group. Participants will undergo:
Clinical assessment (questionnaires on pain, anxiety, body perception, and kinesiophobia).
A Virtual Reality (VR) test (approx. 40 minutes). In VR, participants will judge whether a cylinder presented at different distances and angles is reachable without moving (Perceived Reachable Distance - DMA-p). This will be compared to their Real Reachable Distance (DMA-r).
The goal is to measure the error of judgment to assess PPS representation and check for correlations with body schema disturbances or functional impairment
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with Exclusion
Patients presenting with unilateral segmental exclusion of the upper limb or part of the hand evolving for more than 3 months.
Reachability Judgment Task in VR.
Participants wear an Oculus Quest 2 VR headset. They first perform a motor task to measure Real Reachable Distance (DMA-r). Then, they perform a perceptual task where they must judge, without moving, if a virtual object is reachable (DMA-p). The test evaluates different spatial planes (front, 45° right, 45° left) and heights (shoulder, navel).
Healthy Controls
symptomatic volunteers with no history of upper limb impairment with sequelae.
Reachability Judgment Task in VR.
Participants wear an Oculus Quest 2 VR headset. They first perform a motor task to measure Real Reachable Distance (DMA-r). Then, they perform a perceptual task where they must judge, without moving, if a virtual object is reachable (DMA-p). The test evaluates different spatial planes (front, 45° right, 45° left) and heights (shoulder, navel).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Reachability Judgment Task in VR.
Participants wear an Oculus Quest 2 VR headset. They first perform a motor task to measure Real Reachable Distance (DMA-r). Then, they perform a perceptual task where they must judge, without moving, if a virtual object is reachable (DMA-p). The test evaluates different spatial planes (front, 45° right, 45° left) and heights (shoulder, navel).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Presenting unilateral exclusion symptom of the upper limb or part of the hand evolving for \> 3 months.
* No contraindication to force work in daily activities.
* For patients with finger exclusion: at least 2 perturbed items related to exclusion on tests 3 and 4 of the "Bilan 400 points".
* Affiliated to a social security scheme.
* Able to understand simple orders.
* Age ≥ 18 years.
* No history of upper limb impairment with sequelae.
Exclusion Criteria
* Central neurological pathology.
* Unstabilized psychiatric pathology.
* Communication or comprehension difficulties.
* Under legal protection or unable to consent.
* Pregnant or breastfeeding women.
* Cervical pathology contraindicating VR headset use.
* Epilepsy.
* Upper limb pathology unrelated to exclusion.
* Inability to stand for 40 minutes.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Union de Gestion des Etablissements des Caisses d'Assurance Maladie - Nord Est
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Institut Régional de Médecine Physique et de Réadaptation (IRR), Centre Louis Pierquin.
Nancy, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2025-A02189-40
Identifier Type: OTHER
Identifier Source: secondary_id
IRR-CLP-2023-3
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.